K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway

Cell Cycle

Volumn 12, Issue 11, 2013, Pages 1713-1721

  Poli, Alessandro ^a   Faenza, Irene ^a   Chiarini, Francesca ^b   Matteucci, Alessandro ^b   McCubrey, James A ^c   Cocco, Lucio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CNR   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cell proliferation; Cyclin D3; FELC; K562; Knockdown; Overexpression; PKC ; PLC 1

Indexed keywords

CYCLIN D3; ISOPROTEIN; PHOSPHOLIPASE C BETA1; PROTEIN KINASE C;

ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN K 562; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

MURINAE;

EID: 84878588945     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24806     Document Type: Article

References (49)

1. Rhee SG, Choi KD. Regulation of inositol phospholipid-specific phospholipase C isozymes. J Biol Chem 1992; 267:12393-6; PMID:1319994
2. Raimondi C, Falasca M. Phosphoinositides signalling in cancer: focus on PI3K and PLC. Adv Biol Regul 2012; 52:166-82; PMID:22019900; http://dx.doi. org/10.1016/j.advenzreg.2011.09.016
3. Suh PG, Park JI, Manzoli L, Cocco L, Peak JC, Katan M, et al. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep 2008; 41:415-34; PMID:18593525; http://dx.doi.org/10.5483/BMBRep.2008.41.6.415
4. Bahk YY, Lee YH, Lee TG, Seo J, Ryu SH, Suh PG. Two forms of phospholipase C-beta 1 generated by alternative splicing. J Biol Chem 1994; 269:8240-5; PMID:7510682
5. Kim CG, Park D, Rhee SG. The role of carboxyl-terminal basic amino acids in Gqalpha-dependent activation, particulate association, and nuclear localization of phospholipase C-beta1. J Biol Chem 1996; 271:21187-92; PMID:8702889; http://dx.doi.org/10.1074/jbc.271.35.21187
6. Bahk YY, Song H, Baek SH, Park BY, Kim H, Ryu SH, et al. Localization of two forms of phospholipase C-beta1, a and b, in C6Bu-1 cells. Biochim Biophys Acta 1998; 1389:76-80; PMID:9443606; http://dx.doi.org/10.1016/S0005-2760(97) 00128-8
7. Cocco L, Martelli AM, Gilmour RS, Rhee SG, Manzoli FA. Nuclear phospholipase C and signaling. Biochim Biophys Acta 2001; 1530:1-14; PMID:11341954; http://dx.doi.org/10.1016/S1388-1981(00)00169-4
8. Cocco L, Follo MY, Faenza I, Fiume R, Ramazzotti G, Weber G, et al. Physiology and pathology of nuclear phospholipase C ?1. Adv Enzyme Regul 2011; 51:2-12; PMID:21035488; http://dx.doi.org/10.1016/j. advenzreg.2010.09.015
9. Follo MY, Faenza I, Fiume R, Ramazzotti G, McCubrey JA, Martelli AM, et al. Revisiting nuclear phospholipase C signalling in MDS. Adv Biol Regul 2012; 52:2-6; PMID:21982979; http://dx.doi.org/10.1016/j. advenzreg.2011.09.018
10. Martelli AM, Gilmour RS, Bertagnolo V, Neri LM, Manzoli L, Cocco L. Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. Nature 1992; 358:242-5; PMID:1321347; http://dx.doi.org/10. 1038/358242a0
11. Xu A, Wang Y, Xu LY, Gilmour RS. Protein kinase C alpha-mediated negative feedback regulation is responsible for the termination of insulin-like growth factor I-induced activation of nuclear phospholipase C beta1 in Swiss 3T3 cells. J Biol Chem 2001; 276:14980-6; PMID:11278470; http://dx.doi.org/10.1074/jbc. M009144200
12. Faenza I, Matteucci A, Manzoli L, Billi AM, Aluigi M, Peruzzi D, et al. A role for nuclear phospholipase Cbeta 1 in cell cycle control. J Biol Chem 2000; 275:30520-4; PMID:10913438; http://dx.doi.org/10.1074/jbc. M004630200
13. Fiume R, Ramazzotti G, Teti G, Chiarini F, Faenza I, Mazzotti G, et al. Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression. FASEB J 2009; 23:957-66; PMID:19028838; http://dx.doi.org/10. 1096/fj.08-121244
14. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem 1993; 268:9194-7; PMID:8486620
15. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258:607-14; PMID:1411571; http://dx.doi.org/10.1126/science.1411571
16. Black AR, Black JD. Protein kinase C signaling and cell cycle regulation. Front Immunol 2012; 3:423; PMID:23335926
17. Livneh E, Fishman DD. Linking protein kinase C to cell-cycle control. Eur J Biochem 1997; 248:1-9; PMID:9310352; http://dx.doi. org/10.1111/j.1432-1033. 1997.t01-4-00001.x
18. Newton AC. Lipid activation of protein kinases. J Lipid Res 2009; 50(Suppl):S266-71; PMID:19033211; http://dx.doi.org/10.1194/jlr.R800064-JLR200
19. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998; 332:281-92; PMID:9601053
20. Newton AC. Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab 2010; 298:E395-402; PMID:19934406; http://dx.doi.org/10.1152/ajpendo. 00477.2009
21. Cho W. Membrane targeting by C1 and C2 domains. J Biol Chem 2001; 276:32407-10; PMID:11432875; http://dx.doi.org/10.1074/jbc.R100007200
22. Haughian JM, Reno EM, Thorne AM, Bradford AP. Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer 2009; 125:2556-64; PMID:19672862; http://dx.doi.org/10.1002/ijc.24633
23. Aisiku O, Dowal L, Scarlata S. Protein kinase C phosphorylation of PLC?1 regulates its cellular localization. Arch Biochem Biophys 2011; 509:186-90; PMID:21338571; http://dx.doi.org/10.1016/j. abb.2011.02.006
24. Detjen KM, Brembeck FH, Welzel M, Kaiser A, Haller H, Wiedenmann B, et al. Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J Cell Sci 2000; 113:3025-35; PMID:10934041
25. Frey MR, Clark JA, Bateman NW, Kazanietz MG, Black AR, Black JD. Cell cycle-and protein kinase C-specific effects of resiniferatoxin and resiniferonol 9,13,14-ortho-phenylacetate in intestinal epithelial cells. Biochem Pharmacol 2004; 67:1873-86; PMID:15130764; http://dx.doi.org/10.1016/j. bcp.2004.02.006
26. Alisi A, Spagnuolo S, Napoletano S, Spaziani A, Leoni S. Thyroid hormones regulate DNA-synthesis and cellcycle proteins by activation of PKCalpha and p42/44 MAPK in chick embryo hepatocytes. J Cell Physiol 2004; 201:259-65; PMID:15334660; http://dx.doi. org/10.1002/jcp.20060
27. Wu TT, Hsieh YH, Hsieh YS, Liu JY. Reduction of PKC alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma. J Cell Biochem 2008; 103:9-20; PMID:17486587; http://dx.doi.org/10. 1002/jcb.21378
28. Hu MG, Deshpande A, Enos M, Mao D, Hinds EA, Hu GF, et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res 2009; 69:810-8; PMID:19155308; http://dx.doi.org/10.1158/0008-5472.CAN-08- 2473
29. Li L, Iwamoto Y, Berezovskaya A, Boussiotis VA. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol 2006; 7:1157-65; PMID:17013388; http://dx.doi.org/10.1038/ni1398
30. Blagosklonny MV. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors. Cell Cycle 2011; 10:2295-8; PMID:21715978; http://dx.doi. org/10.4161/cc.10.14.16819
31. Belletti B, Baldassarre G. New light on p27(kip1) in breast cancer. Cell Cycle 2012; 11:3701-2; PMID:22895010; http://dx.doi.org/10.4161/cc.21573
32. Speroni J, Gottifredi V. p21 Regulates the cell cycle... or the other way around? Cell Cycle 2011; 10:3430; PMID:22024928; http://dx.doi.org/10.4161/cc. 10.20.17530
33. De Vita F, Riccardi M, Malanga D, Scrima M, De Marco C, Viglietto G. PKC-dependent phosphorylation of p27 at T198 contributes to p27 stabilization and cell cycle arrest. Cell Cycle 2012; 11:1583-92; PMID:22441823; http://dx.doi.org/10.4161/cc.20003
34. McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, et al. Advances in targeting signal transduction pathways. Oncotarget 2012; 3:1505-21; PMID:23455493
35. Follo MY, Mongiorgi S, Clissa C, Paolini S, Martinelli G, Martelli AM, et al. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Leukemia 2012; 26:2474-82; PMID:22596089; http://dx.doi.org/10.1038/leu.2012.133
36. Follo MY, Finelli C, Mongiorgi S, Clissa C, Chiarini F, Ramazzotti G, et al. Synergistic induction of PI-PLC?1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia 2011; 25:271-80; PMID:21109771; http://dx.doi.org/10.1038/leu.2010.266
37. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012; 3:1068-111; PMID:23085539
38. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, et al. Involvement of Akt and mTOR in chemotherapeutic-and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011; 10:3003-15; PMID:21869603; http://dx.doi.org/10.4161/cc.10.17.17119
39. Ramazzotti G, Faenza I, Gaboardi GC, Piazzi M, Bavelloni A, Fiume R, et al. Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. Cell Signal 2008; 20:2013-21; PMID:18694821; http://dx.doi.org/10.1016/j. cellsig.2008.07.009
40. Casimiro MC, Pestell RG. Cyclin d1 induces chromosomal instability. Oncotarget 2012; 3:224-5; PMID:22538871
41. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36:131-49; PMID:12814430; http://dx.doi.org/10.1046/j.1365-2184.2003.00266.x
42. Hocevar BA, Morrow DM, Tykocinski ML, Fields AP. Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation. J Cell Sci 1992; 101:671-9; PMID:1522149
43. Ellis MV, James SR, Perisic O, Downes CP, Williams RL, Katan M. Catalytic domain of phosphoinositidespecific phospholipase C (PLC). Mutational analysis of residues within the active site and hydrophobic ridge of plcdelta1. J Biol Chem 1998; 273:11650-9; PMID:9565585; http://dx.doi.org/10.1074/jbc.273.19.11650
44. Johnson N, Shapiro GI. Cyclin-dependent kinase 4/6 inhibition in cancer therapy. Cell Cycle 2012; 11:3913; PMID:23032266; http://dx.doi.org/10.4161/cc. 22390
45. Pagliuca FW, Collins MO, Choudhary JS. Coordinating cell cycle progression via cyclin specificity. Cell Cycle 2011; 10:4195-6; PMID:22156915; http://dx.doi. org/10.4161/cc.10.24.18395
46. Darzynkiewicz Z. Redundancy in response to DNA damage: the key to protection of genome integrity. Cell Cycle 2011; 10:3425; PMID:22024932; http://dx.doi. org/10.4161/cc.10.20.17525
47. Siu KT, Rosner MR, Minella AC. An integrated view of cyclin E function and regulation. Cell Cycle 2012; 11:57-64; PMID:22186781; http://dx.doi. org/10.4161/cc.11.1.18775
48. Divecha N, Banfic H, Treagus JE, Vann L, Irvine RF, D'Santos C. Nuclear diacylglycerol, the cell cycle, the enzymes and a red herring (or how we came to love phosphatidylcholine). Biochem Soc Trans 1997; 25:571-5; PMID:9191158
49. Hansra G, Garcia-Paramio P, Prevostel C, Whelan RD, Bornancin F, Parker PJ. Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes. Biochem J 1999; 342:337-44; PMID:10455020; http://dx.doi.org/10.1042/0264-6021:3420337